Skip to main content

Table 1 Baseline demographic, clinical, and laboratory characteristics of the study patients according to tertiles of fibrinogen

From: The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis

  Total (N = 293) Tertile 1 (N = 99) Tertile 2 (N = 97) Tertile 3 (N = 97) P
FIB, g/L 1.50 (1.02–2.18) 0.86 (0.70–1.03) 1.51 (1.38–1.72) 2.59 (2.18–3.33) < 0.001
Male, n (%) 183 (62.5) 62 (62.6) 60 (61.9) 61 (62.9) 0.988
Age, years 53 (41–64) 51 (33–64) 56 (39–62) 55 (46–66) 0.118
ANC, \(\times \hspace{0.17em}\)109/L 1.32 (0.69–2.35) 1.04 (0.57–2.11) 1.36 (0.77–2.24) 1.55 (0.81–2.71) 0.057
HB, g/L 86 (71–100) 84 (77–95) 90 (73–107) 82 (68–97) 0.111
PLT,\(\times \hspace{0.17em}\)109/L 43 (24–72) 31 (18–52) 45 (25–80) 54 (32–97) < 0.001
ALT, U/L 67.1 (36.3–149.1) 98.6 (50.6–235.4) 77.6 (32.4–143.2) 50.1 (28.4–82.3) < 0.001
AST, U/L 91 (46.1–203.8) 178.5 (78.1–411.0) 90.2 (45.1–198.1) 61.0 (39.5–121.65) < 0.001
LDH, U/L 676 (394.0–1308.5) 1004 (580.0–1793.0) 646 (354.5–1101.0) 540 (379.5–934.0) < 0.001
TG, mmol/L 2.47 (1.71–3.70) 2.78 (1.77–4.04) 2.52 (1.89–3.67) 2.01 (1.58–3.18) 0.015
Ferritin, ug/L 4739 (1522–12,798) 8133 (2000–20,000) 3639 (1613–9558) 2841 (1494–7095) < 0.001
sCD25, ng/L 33,480 (17,442–51,668) 40,042 (22,660–55,919) 26,920 (14,266–48,289) 32,939 (16,018–47,762) 0.024
β2-MG, mg/L 5.97 (4.41–8.53) 5.91 (4.19–8.53) 7.63 (4.85–9.28) 5.69 (3.88–8.04) 0.030
Fever, °C 39.5 (39.0–40.0) 39.6 (39.0–40.0) 39.4 (39.0–40.0) 39.3 (39.0–40.0) 0.143
Splenomegaly (%) 260 (88.7) 90 (90.9) 88 (90.7) 82 (84.5) 0.278
Lymphadenopathy (%) 152 (51.9) 45 (45.5) 52 (53.6) 55 (56.7) 0.265
Hemophagocytic (%) 260 (88.7) 88 (88.9) 85 (87.6) 87 (89.7) 0.900
HScore, points 234 (205–269) 255 (224–283) 235 (210–274) 219 (179–244) < 0.001
EBV infection (%) 148 (50.5) 65 (65.7) 44 (45.4) 39 (40.2) 0.001
Etiology 0.120
 MHLH (%) 169 (57.7) 65 (65.7) 50 (51.5) 54 (55.7)  
 Non-MHLH (%) 124 (42.3) 34 (34.3) 47 (48.5) 43 (44.3)  
Treatment 0.960
 Chem ± HLH-94 (%) 167 (57.0) 58 (58.6) 53 (54.6) 56 (57.7)  
 GC ± IVIG ± CsA ± VP16 (%) 112 (38.2) 36 (36.4) 40 (41.2) 36 (37.1)  
 Support (%) 14 (4.8) 5 (5.1) 4 (4.1) 5 (5.2)  
  1. Italics indicate statistical significance (P < 0.05)
  2. FIB fibrinogen, ANC absolute neutrophil count, HB hemoglobin, PLT platelet, ALT alanine transaminase, AST aspartate transaminase, LDH lactate dehydrogenase, ALB albumin, TG triglyceride, sCD25 soluble interleukin-2 receptor, β2-MG beta2-microglobulin, EBV Epstein-Barr virus, MHLH malignancy-associated haemophagocytic lymphohistiocytosis, Non-MHLH non-malignancy associated haemophagocytic lymphohistiocytosis, GC glucocorticoid, IVIg intravenous immunoglobulins, CsA cyclosporine, VP16 etoposide